GlaxoSmithKline Pays Billions for New Cancer Immunotherapy

The British pharmaceutical company GlaxoSmithKline forges a billion-dollar alliance with the US biotech company iTeos to develop a new cancer immunotherapy. In the course of the partnership, iTeos can hope for payments of up to two billion dollars, as both companies announced on Monday.

This gives Glaxo access to an antibody from the US company that is in early clinical development for the treatment of solid tumors. The two companies want to jointly market the cancer drug in the United States and share possible profits. Outside the USA, Glaxo receives an exclusive license for the antibody. In the coming year, the British and iTeos want to start studies in which the use of the agent will be tested together with the cancer drug Dostarlimab from Glaxo.